Value through Innovation27 July 2016

Clinical Study Results

  • MOTENS ® - Hypertension
    Clinical Study Number 231.215
    Study Indication Hypertension
    Product MOTENS ®
    Generic Name Lacidipine
    Lab Code
    Clinical Phase III
    Study Title

    Lacidipine in Medical Practice: Incidence of Rare Adverse Drug Reactions during Long-term Therapy. 1st, 2nd and 3rd Follow-up Study - Long-term Use in the 2nd, 3rd, 4th and 5th Treatment Year.

    Study Document Trial synopsis 231.215 english
  • MOTENS ® - Hypertension
    Clinical Study Number 231.336
    Study Indication Hypertension
    Product MOTENS ®
    Generic Name Lacidipine
    Lab Code
    Clinical Phase IV
    Study Title

    A randomised, parallel-group, double-blind, double-dummy study to compare the effects of lacidipine versus bendrofluazide on markers of platelet activation and haemorheological factors in hypertensive patients.

    Study Document Trial synopsis 231.336_CO english
  • MOTENS ® - Angina Pectoris
    Clinical Study Number 231.339
    Study Indication Angina Pectoris
    Product MOTENS ®
    Generic Name Lacidipine
    Lab Code
    Clinical Phase IIb
    Study Title

    A randomised, double-blind, placebo-controlled, multi-centre, parallel group, dose ranging study to investigate the efficacy and safety of lacidipine in chronic stable angina. Lacidipine In Stable Angina (LISA)

    Study Document Trial synopsis 231.339 english
  • MOTENS ® - Hypertension
    Clinical Study Number 231.340
    Study Indication Hypertension
    Product MOTENS ®
    Generic Name Lacidipine
    Lab Code
    Clinical Phase IV
    Study Title

    Observation of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension, under normal conditions compared with an open clinical trial.

    Study Document Trial synopsis 231.340 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.